Drugmaker Pfizer Inc. is in talks with regulators over a likely change to arthritis drug Bextras label to carry a strict warning alerting doctors of the risk of a potentially deadly skin reaction, the company said in a regulatory filing. 

Pfizer, whose shares fell nearly 3 percent Monday morning, also said in the filing it is under investigation by New York and Connecticut in connection with potentially improper promotion of drugs for uses other than those approved by U.S. regulators.

Pfizer also said it has initiated an internal probe relating to its sales operations in Croatia.

A Pfizer spokesman declined to comment on the investigation or its talks with the U.S. Food and Drug Administration over Bextra.

Prudential Securities analyst Tim Anderson said the warning on Bextra, which is in the same class of drugs as Pfizers Celebrex and Merck & Co.s withdrawn arthritis drug Vioxx, suggests the commercial future of Bextra is at risk.

Pfizer said it is talking to regulators about carrying a black box warning that it might result in a rare, but sometimes fatal skin disorder called Stevens-Johnson syndrome.

Launched in 2001, Bextra had sales last year of $687 million.

In the New York investigation, Pfizer said it has received a letter from Attorney General Eliot Spitzers office requesting documents and information on clinical trials of certain drugs for uses other than those approved by the U.S. Food and Drug Administration. Pfizer said the probe involved the possible promotion of products for unapproved uses.

Pfizer said it received a letter from the Office of the Attorney General of the State of Connecticut requesting similar materials concerning its antidepressant Zoloft.

Pfizer spokesman Paul Fitzhenry said both investigations were new, but declined to specify which drugs the New York attorney general was investigating. A spokesman for Spitzers office declined to comment.

Pfizer also said it has voluntarily provided the Department of Justice and the Securities and Exchange Commission with information regarding an internal probe of certain potentially improper payments made in connection with foreign sales activities in Croatia.

Pfizers shares fell 79 cents to $28.00 Monday on the New York Stock Exchange.



We're here to help!

We live by our creed of "helping those who need it most" and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked    may be required for submission.
  1. I'm an attorney

Bextra, Celebrex MDL judge sets first Bextra trial

On the heels of the $4.85 Billion Vioxx settlement, the Multi-District Litigation (MDL) Court for the...

Bextra

What is Bextra? Bextra is valdecoxib-based drug that is administered orally. Bextra is used as...

Health Canada Prohibits Sale Of Bextra In Canada

Following a review of safety information, Health Canada is informing the public that Bextra, an...

Bextra's Return Barred by Health Canada

Bextra is a member of a class of drugs known as cox-2 inhibitors. Better known cox-2s are Celebrex,...

FDA Rejects Bextra-Like Drug

The FDA has decided not to approve a special formulation of Pfizer's recalled pain reliever Bextra that...

SEC asking Pfizer for Bextra, Celebrex Data

Pfizer Inc. is responding to a request from the Securities and Exchange Commission for information and...

Impressed with the Beasley Allen staff

I am very impressed with the Beasley Allen staff. They were very courteous and patiently explained the aspects of my claim in a way I could understand. If I ever have any need of an attorney in the future I will turn to Beasley Allen.

—Philip